ClinicalTrials.gg
Enrolling by invitationNCT05202977Updated Jan 24, 2022

Safety and Efficacy of SinocrownTM Transcatheter Aortic Valve Replacement System

An interventional study of SinocrownTM Transcatheter Aortic Valve Replacement System in Transcatheter Aortic Valve Replacement, sponsored by Lepu Medical Technology (Beijing) Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2022-01-24.

Sponsored by Lepu Medical Technology (Beijing) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Apr 2021, registered Dec 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
42nd of 47
10 · median 120
Started
2021
with 6 others
No phase
37 of 69
20 open now
Primary completion
2021-08
later than 2 of 50 live
Registered
28th of 69
by date

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 42nd largest by planned enrollment of the 47 interventional ones that give a count, is one of 7 that started in 2021, is one of 37 with no phase, reaches primary completion later than 2 of the 50 other live ones, and was the 28th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

This study was designed to preliminary verify the safety and of efficacy of SinocrownTM Transcatheter Aortic Valve Replacement System With accessories in patients with symptomatic, calcified and severe aortic stenosis using objective performance criteria

Read the detailed description

This prospective, single-center, single-arm clinical trial was designed to preliminary confirm the safety and efficacy of SinocrownTM transcatheter aortic valve system with accessories.

According to the inclusion and exclusion criteria, 10 patients were enrolled and implanted with SinocrownTM .Patients will been followed up 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years after valve implantation. The main follow-up included clinical symptoms and signs, cardiac ultrasound, etc. The primary endpoint was device success after TAVR, Secondary endpoints included procedural success, all-cause mortality, myocardial infarction, disabling stroke, severe bleeding, acute kidney injury, permanent pacemaker implantation, vascular complications, other complication, MACCEs, valvular function , cardiac function improvement, quality of life of patients.

03

Conditions studied

  • Transcatheter Aortic Valve Replacement

Keywords

  • aortic stenosis
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 65 years ;
  2. Autologous degenerative aortic stenosis(evaluated by echocardiography: transaortic valve pressure gradient ≥40mmHg , or transaortic valve blood flow rate ≥4m/s, or aortic Valve area\<1.0cm2, or AVA \<0.5cm2 /m2)
  3. Patients with aortic annulus size≥17.5mm and ≤29mm (echocardiography measurement);
  4. The diameter of the ascending aorta of the patient was \< 45mm.
  5. Appear obvious symptoms caused by aortic stenosis, class Ⅱ to IV;
  6. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.
  7. Subjects are willing to accept all clinical follow-up.
  8. The cardiologist and cardiac surgeon evaluated the subject as unsuitable for surgical treatment (the risk of death or irreversible complications within 30 days after operation is expected to be above 50% , or comorbidities such as prior chest radiotherapy, liver failure, diffuse severe calcification of the aorta, extreme weakness, etc.). Or Moderate or higher surgical risk (STS score ≥ 4%).

Exclusion criteria

Exclusion Criteria:

  1. defined as Q-wave myocardial infarction or non-Q-wave myocardial infarction with CK-MB level ≥ 2 times the value and / or Tn increase.
  2. Subjects with congenital unicuspid, without calcification.
  3. Any therapeutic or traumatic cardiac surgery within 30 days (within 3 months in case of drug-eluting stents implantation)
  4. The patient's heart has been implanted with other artificial heart valves, artificial rings, or severe mitral annulus calcification (MAC), severe (> 3 +) mitral insufficiency.
  5. Hematological abnormalities, including leukopenia (WBC\<3×109/L), acute anemia (HB \<90g/L), thrombocytopenia (\<50×109/L), bleeding constitution and coagulopathy ;
  6. Subjects with hemodynamic instability, requiring continuous mechanical heart assistance.
  7. Subjects who need emergency surgery for any reason;
  8. Hypertrophic cardiomyopathy with or without obstruction;
  9. Severe left ventricular dysfunction, (LVEF) \<20%;
  10. The echocardiogram indicates the presence of a thrombus or vegetation;
  11. A history of active peptic ulcer or upper gastrointestinal bleeding within 3 months;
  12. Are allergic to nickel titanium alloys or contrast agents, and cannot tolerate anticoagulation and antiplatelet therapy;
  13. Cerebrovascular accident occurred within 6 months, including ;
  14. renal insufficiency(creatinine> 3.0mg/dL) and/or end-stage renal disease requiring Renal dialysis;
  15. \< 12 months;
  16. Significant aortic diseases, including abdominal aortic or thoracic aortic aneurysm(defined as maximum lumen diameter > 50mm, obvious distortion), atherosclerosis of the aortic arch(especially bulge with thickness > 5mm or ulceration), narrowing of the abdominal or thoracic aorta(especially calcification and irregular surface), and severe curvature of the thoracic aorta;
  17. The iliac-femoral artery cannot be inserted with a guide sheath of 22F or above, such as severely obstructed with calcification, severely tortuous or vessel diameter less than 6mm;
  18. Screening participant who is participating in other drug or medical device clinical trials;
  19. Active infective endocarditis or other active infections;
  20. Anatomically, the approach or aortic root is not suitable for TAVR (such as a high risk of coronary artery occlusion).
  21. Other conditions considered by the investigator to be inappropriate for participation in this clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    SinocrownTM Transcatheter Aortic Valve Replacement System

    The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.

    Device: SinocrownTM Transcatheter Aortic Valve Replacement System

Interventions

  • DeviceSinocrownTM Transcatheter Aortic Valve Replacement System

    Subjects receiving SinocrownTM Transcatheter Aortic Valve Replacement System of Lepu Medical

06

What researchers measure

Primary outcomes

  1. device success

    Immediate postoperative device success was defined as : successfully loading the valve into the delivery system, sending it to the target site through the delivery system, accurately releasing the artificial aortic valve and completely withdrawing the delivery system (valve orifice area \> 1.2cm2, mean aortic gradient\< 20mmhg or maximal aortic valve velocity \< 3 m/ s, and there is no moderate or severe valve stenosis)

    Time frame: immediate post-surgical

Secondary outcomes

  1. Procedural success

    Device success without death and aortic valve reintervention during operation

    Time frame: immediate post-surgical

  2. All-cause mortality

    including cardiac, non-cardiac and unexplained deaths

    Time frame: immediate post-surgical, 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years

  3. Myocardial infarction

    Rate of patients with myocardial infarction

    Time frame: immediate post-surgical, 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years

  4. Rate of disabling stroke

    Disabling stroke was defined as mRS ≥ 2, and the mRS score increased by more than 1 point compared with the last visit

    Time frame: 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years

  5. Rate of Severe bleeding(life-threatening or disabling)

    Severe degree was defined as type 3a or above(according to BARC)

    Time frame: 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years

  6. acute kidney injury

    Rate of patients with acute kidney injury

    Time frame: 7 days after procedure/prior to discharge, 30 days after procedure

  7. permanent pacemaker implantation

    Rate of patients implanted with permanent pacemaker

    Time frame: 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years

  8. vascular complications

    Vascular complications mainly include dissection, occlusion, rupture and bleeding of access vessels.

    Time frame: immediate post-surgical, 7 days after procedure/prior to discharge

  9. other operative complication

    including conversion to surgery, unexpected cardiopulmonary mechanical assistance, coronary artery occlusion, ventricular septal perforation, mitral valve injury or loss of function, pericardial tamponade, endocarditis, valve thrombosis, valve ectopic (displacement, embolization, misrelease), and so on.

    Time frame: immediate post-surgical, 7 days after procedure/prior to discharge

  10. The incidence of major adverse cardiovascular and cerebrovascular events during the trial(MACCEs)

    Incidence of MACCEs (including mortality, stroke, myocardial infarction, reoperation, arrhythmias and conduction blocks) during the trial.

    Time frame: immediate post-surgical, 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months, 2 years, 3 years, 4 years and 5 years

  11. Valve and heart function

    Doppler echocardiography was used to evaluate the valve performance at each follow-up point, including valve orifice area, mean aortic gradient, degree of valve regurgitation, left ventricular ejection fraction LVEF, end diastolic left ventricular inner diameter LVEDd, moderate or above perivalvular leakage PVL, and degree of aortic stenosis.

    Time frame: immediate post-surgical, 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months

  12. Cardiac function improvement

    Cardiac function improvement is accessed by NYHA cardiac function classification increases from baseline to discharge, 30 days, 6 months, 12 months

    Time frame: 7 days after procedure/prior to discharge, 30 days, 6 months, 12 months

  13. Quality of life of patients

    Quality of Life of patients accessed by EuroQol-5 Dimensions (EQ-5D) Questionnaire. The higher scores mean a better health state. Recording changes from baseline to 30 days, 6 months, 12 months

    Time frame: 30 days, 6 months, 12 months

07

Study locations

1 site
  • Hefei High-tech Cardiovascular hospital
    Hefei, Anhui, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2021, 4 months.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's 4 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2021
First posted
Jan 24, 2022
StartActual
Apr 6, 2021
Primary completionActual
Aug 7, 2021
CompletionEst.
Aug 2026
Last update
Jan 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05202977
Responsible party
Sponsor
First posted
Jan 24, 2022
Start date
Apr 6, 2021
Primary completion
Aug 7, 2021
Completion
Aug 2026 (estimated)
Last update
Jan 24, 2022

Study contacts

Yongjian Wu
study chair · Heifei High-tech Cardiovascular hospital
Weiyi Fang
study chair · Heifei High-tech Cardiovascular hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion